Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. (Q53175509)

From Wikidata

Jump to navigation Jump to search

scientific article published on 10 February 2016

Language	Label	Description	Also known as
English	Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.	scientific article published on 10 February 2016

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26874885%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26874885%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

phase III clinical trial

0 references

multicenter clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26874885%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26874885%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Giovanni Grignani

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26874885%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Sebastian Bauer

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26874885%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26874885%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Hans J. Gelderblom

5

object named as

Hans Gelderblom

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26874885%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Peter Hohenberger

12

object named as

Peter Hohenberger

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26874885%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

16

object named as

Axel Le Cesne

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26874885%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

George D Demetri

17

object named as

George D Demetri

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26874885%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

2

object named as

Sant Chawla

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26874885%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Shreyaskumar Patel

18

object named as

Shreyaskumar R Patel

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26874885%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Patrick Schöffski

1

object named as

Patrick Schöffski

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26874885%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

author name string

Antoine Italiano

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26874885%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Edwin Choy

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26874885%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Veridiana Camargo

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26874885%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

David D'Adamo

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26874885%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Matthew Guo

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26874885%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Bartosz Chmielowski

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26874885%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

language of work or name

0 references

publication date

10 February 2016

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26874885%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26874885%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

387

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26874885%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

10028

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26874885%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1629-1637

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26874885%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Soft tissue sarcoma: an update on systemic treatment options for patients with advanced disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901283-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Incidence of soft tissue sarcoma and beyond: a population-based prospective study in 3 European regions.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901283-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901283-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Sarcoma and skin radiation oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901283-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901283-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901283-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901283-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901283-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901283-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901283-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901283-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901283-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901283-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901283-0

7 January 2021

based on heuristic

inferred from DOI database lookup

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901283-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901283-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901283-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901283-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901283-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901283-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901283-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901283-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(15)01283-0

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26874885%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26874885%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53175509&oldid=1835243313"